Mangoceuticals, Inc. (MGRX) — Financial statements
Income statement, balance sheet, and cash flow for Mangoceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.46↓26.0% | 0.62↓15.8% | 0.73↑8083.2% | 0.01 | 0.00 | |
| Cost of Revenue | 0.21↓12.8% | 0.24↓21.4% | 0.30↑7236.6% | 0.00 | 0.00 | |
| Gross Profit | 0.25↓34.1% | 0.38↓11.9% | 0.43↑8796.9% | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 16↑147.7% | 6↑93.4% | 3↑102.0% | 2 | 0.00 | |
| Selling & Marketing Expenses | 0.82↓44.4% | 1↓29.5% | 2↑494.4% | 0.35 | 0.00 | |
| SG&A Expenses | 17↑111.7% | 8↑45.8% | 5↑171.3% | 2↑11295.2% | 0.02 | |
| Other Expenses | 3↑491.4% | 0.45↓89.3% | 4 | 0.00 | 0.00 | |
| Operating Expenses | 19↑132.3% | 8↓13.5% | 10↑383.4% | 2↑11295.2% | 0.02 | |
| Total Costs & Expenses | 20↑128.4% | 9↓13.7% | 10↑397.4% | 2↑11318.5% | 0.02 | |
| Operating Results | ||||||
| Operating Income | -19↓140.3% | -8↑13.5% | -9↓362.9% | -2↓11267.5% | -0.02 | |
| Depreciation & Amortization | 2↑139.0% | 0.72↑2799.0% | 0.02↑544.3% | 0.00 | 0.00 | |
| EBITDA | -19↓136.3% | -8↑1.6% | -8↓307.2% | -2↓11245.4% | -0.02 | |
| EBIT | -21↓136.3% | -9↓7.1% | -8↓307.6% | -2↓11267.5% | -0.02 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.10↓655.6% | -0.01 | 0.00↑100.0% | -0.01↓3476.2% | -0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.10↑655.6% | 0.01 | 0.00↓100.0% | 0.01↑3476.2% | 0.00 | |
| Non-Operating Income | 1↑91.9% | 0.72↑165.6% | -1 | 0.00 | 0.00 | |
| Other Income / Expenses | -1↓102.5% | -0.74↓11454.9% | 0.01↑200.0% | -0.01↓3476.2% | -0.00 | |
| Income Before Tax | -21↓137.1% | -9↑5.5% | -9↓361.1% | -2↓11187.8% | -0.02 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -21↓137.1% | -9↑5.5% | -9↓361.1% | -2↓11187.8% | -0.02 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -21↓137.1% | -9↑5.5% | -9↓361.1% | -2↓11187.8% | -0.02 | |
| Bottom-Line Net Income | -21↓137.1% | -9↑5.5% | -9↓361.1% | -2↓11187.8% | -0.02 | |
| EPS (Basic) | -2.05↑53.4% | -4.40↑48.7% | -8.58↓395.7% | -1.73↓9679.1% | -0.02 | |
| EPS (Diluted) | -2.05↑53.4% | -4.40↑48.7% | -8.58↓395.7% | -1.73↓9679.1% | -0.02 | |
| Weighted Average Shares | 10↑408.9% | 2↑84.3% | 1↓7.0% | 1↑15.7% | 1.00 | |
| Weighted Average Diluted Shares | 10↑408.9% | 2↑84.3% | 1↓7.0% | 1↑15.7% | 1.00 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.